GSTM1 and diabetic cardiomyopathy: Additionally, while the association of glyco Hb elevation with an advanced clinical cardiovascular syndrome described as diabetic cardiomyopathy (beyond the classic cardiac risk factors associated with diabetes mellitus) has also been well documented, the use of advanced glycation end products (AGE) as both a marker of, and treatment target for the early diastolic hemodynamic changes of diabetic cardiomyopathy, has been suggested but is less well characterized6–8,14.